The Organ-on-Chip market is projected to reach $2.5 billion by 2036, at a CAGR of 22.2% from 2026 to 2036. The growth of this market is primarily fueled by increasing demand for alternatives to animal testing, rising R&D costs in drug discovery, and growing regulatory acceptance of microphysiological systems as valid preclinical evidence. Additionally, the FDA Modernization Act 2.0's removal of the statutory requirement for animal-based safety and efficacy data, expanding NIH investment in tissue chip technologies, and rising demand for human-relevant preclinical models are expected to create substantial growth opportunities for market participants.
The key players operating in the Organ-on-Chip market are Emulate, Inc. (U.S.), MIMETAS B.V. (Netherlands), CN Bio Innovations Ltd. (U.K.), TissUse GmbH (Germany), InSphero AG (Switzerland), Nortis, Inc. (U.S.), AlveoliX AG (Switzerland), Hesperos, Inc. (U.S.), Kirkstall Ltd. (U.K.), Cherry Biotech (France), AIM Biotech Pte. Ltd. (Singapore), SynVivo, Inc. (U.S.), Quris-AI (Israel), and Altis Biosystems, Inc. (U.S.).
The Organ-on-Chip market study presents historical market data value (2025), estimated current data (2026), and forecasts for 2036. This market is segmented by organ type, type, product & service, technology, cell source, application, end user, and geography.
Among all the organ types, the Liver-on-Chip segment is expected to account for the largest share of the Organ-on-Chip market in 2026. The dominant position of this segment is primarily attributed to the liver's central role in drug metabolism and its position as the most frequent site of drug-induced toxicity, making liver-on-chip models a priority application for hepatotoxicity and drug metabolism studies. However, Multi-Organ-on-Chip platforms are projected to register the fastest growth during the forecast period, driven by increasing pharmaceutical industry interest in modeling systemic drug distribution and inter-organ toxicity beyond single-organ testing.
Among all the types, the Single-Organ-on-Chip segment is expected to account for the largest share of the Organ-on-Chip market in 2026, primarily due to its more established validation base and broader current adoption across routine drug screening and toxicology applications. Human-on-Chip platforms, meanwhile, are projected to register the fastest growth, driven by growing research investment in comprehensive, systemic physiological models capable of representing whole-body drug response.
Among all the product and service segments, Products are projected to account for the largest market share in 2026, reflecting sustained capital investment in organ-on-chip devices and instrumentation by pharmaceutical companies and research institutions building internal testing capabilities. Services, however, are projected to register the fastest growth, driven by growing demand among smaller biotechnology companies and research organizations to access organ-on-chip capabilities through contract research and testing services without significant upfront capital investment.
Among all the applications, the Drug Discovery & Development segment is projected to hold the largest market share in 2026, consistent with organ-on-chip technology's primary current use case in target validation, drug screening, and pharmacokinetic studies. Personalized & Precision Medicine is projected to register the fastest growth, driven by increasing use of patient-derived cell-based organ-on-chip models to predict individual treatment response.
Among all the end users, Pharmaceutical & Biotechnology Companies are expected to account for the largest share of the market in 2026, reflecting the technology's growing integration into preclinical drug development pipelines. Contract Research Organizations, on the other hand, are projected to register the fastest growth, driven by increasing outsourcing of organ-on-chip testing and disease modeling services by pharmaceutical sponsors seeking specialized expertise without in-house capability investment.
Among all the geographies, North America is expected to account for the largest share of the Organ-on-Chip market in 2026, supported by the presence of leading organ-on-chip technology developers, substantial NIH funding through the Tissue Chip for Drug Screening program, and the FDA Modernization Act 2.0's direct regulatory pathway for organ-on-chip data in U.S. drug development submissions. Asia-Pacific, however, is projected to register the highest CAGR during the forecast period of 2026-2036, driven by expanding pharmaceutical and biotechnology R&D investment in China, Japan, South Korea, and India, growing academic research capacity in microfluidics and tissue engineering, and increasing government support for advanced life sciences research infrastructure.
The key players operating in the Organ-on-Chip market are Emulate, Inc. (U.S.), MIMETAS B.V. (Netherlands), CN Bio Innovations Ltd. (U.K.), TissUse GmbH (Germany), InSphero AG (Switzerland), Nortis, Inc. (U.S.), AlveoliX AG (Switzerland), Hesperos, Inc. (U.S.), Kirkstall Ltd. (U.K.), Cherry Biotech (France), AIM Biotech Pte. Ltd. (Singapore), SynVivo, Inc. (U.S.), Quris-AI (Israel), and Altis Biosystems, Inc. (U.S.).
The Organ-on-Chip market study presents historical market data value (2025), estimated current data (2026), and forecasts for 2036. This market is segmented by organ type, type, product & service, technology, cell source, application, end user, and geography.
Among all the organ types, the Liver-on-Chip segment is expected to account for the largest share of the Organ-on-Chip market in 2026. The dominant position of this segment is primarily attributed to the liver's central role in drug metabolism and its position as the most frequent site of drug-induced toxicity, making liver-on-chip models a priority application for hepatotoxicity and drug metabolism studies. However, Multi-Organ-on-Chip platforms are projected to register the fastest growth during the forecast period, driven by increasing pharmaceutical industry interest in modeling systemic drug distribution and inter-organ toxicity beyond single-organ testing.
Among all the types, the Single-Organ-on-Chip segment is expected to account for the largest share of the Organ-on-Chip market in 2026, primarily due to its more established validation base and broader current adoption across routine drug screening and toxicology applications. Human-on-Chip platforms, meanwhile, are projected to register the fastest growth, driven by growing research investment in comprehensive, systemic physiological models capable of representing whole-body drug response.
Among all the product and service segments, Products are projected to account for the largest market share in 2026, reflecting sustained capital investment in organ-on-chip devices and instrumentation by pharmaceutical companies and research institutions building internal testing capabilities. Services, however, are projected to register the fastest growth, driven by growing demand among smaller biotechnology companies and research organizations to access organ-on-chip capabilities through contract research and testing services without significant upfront capital investment.
Among all the applications, the Drug Discovery & Development segment is projected to hold the largest market share in 2026, consistent with organ-on-chip technology's primary current use case in target validation, drug screening, and pharmacokinetic studies. Personalized & Precision Medicine is projected to register the fastest growth, driven by increasing use of patient-derived cell-based organ-on-chip models to predict individual treatment response.
Among all the end users, Pharmaceutical & Biotechnology Companies are expected to account for the largest share of the market in 2026, reflecting the technology's growing integration into preclinical drug development pipelines. Contract Research Organizations, on the other hand, are projected to register the fastest growth, driven by increasing outsourcing of organ-on-chip testing and disease modeling services by pharmaceutical sponsors seeking specialized expertise without in-house capability investment.
Among all the geographies, North America is expected to account for the largest share of the Organ-on-Chip market in 2026, supported by the presence of leading organ-on-chip technology developers, substantial NIH funding through the Tissue Chip for Drug Screening program, and the FDA Modernization Act 2.0's direct regulatory pathway for organ-on-chip data in U.S. drug development submissions. Asia-Pacific, however, is projected to register the highest CAGR during the forecast period of 2026-2036, driven by expanding pharmaceutical and biotechnology R&D investment in China, Japan, South Korea, and India, growing academic research capacity in microfluidics and tissue engineering, and increasing government support for advanced life sciences research infrastructure.
Key Questions Answered in the Report:
- What is the current revenue generated by the Organ-on-Chip market globally?
- At what rate is the Organ-on-Chip market demand projected to grow for the next 10 years?
- What are the historical market sizes and growth rates of the Organ-on-Chip market?
- What are the major factors impacting the growth of this market at the regional and country levels? What are the major opportunities for existing players and new entrants in the market?
- Which segments in terms of organ type, type, product & service, technology, cell source, application, and end user are expected to create major traction for the manufacturers in this market?
- What are the key geographical trends in this market? Which regions/countries are expected to offer significant growth opportunities for the manufacturers operating in the Organ-on-Chip market?
- Who are the major players in the Organ-on-Chip market? What are their specific product offerings in this market?
- What are the recent strategic developments in the Organ-on-Chip market? What are the impacts of these strategic developments on the market?
Table of Contents
1. Introduction
2. Research Methodology
4. Market Overview
5. Organ-on-Chip Market, by Organ Type
6. Organ-on-Chip Market, by Type
7. Organ-on-Chip Market, by Product & Service
8. Organ-on-Chip Market, by Technology
9. Organ-on-Chip Market, by Cell Source
10. Organ-on-Chip Market, by Application
11. Organ-on-Chip Market, by End User
12. Organ-on-Chip Market, by Geography
13. Competitive Landscape
14. Company Profiles
15. Appendix
List of Tables
List of Figures
Companies Mentioned
- Emulate, Inc.
- MIMETAS B.V.
- CN Bio Innovations Ltd.
- TissUse GmbH
- InSphero AG
- Nortis, Inc.
- AlveoliX AG
- Hesperos, Inc.
- Kirkstall Ltd.
- Cherry Biotech
- AIM Biotech Pte. Ltd.
- SynVivo, Inc.
- Quris-AI
- Altis Biosystems, Inc. (U.S.).
